摘要
目的:观察小剂量尿激酶(UK)与低分子肝素联合治疗不稳定型心绞痛(UAP)的临床疗效。方法:158例患者随机分成治疗组和对照组,每组79例。治疗组应用UK0.5万IU/kg,于30min内静脉滴入,连续3d;在第1天静脉滴注UK前1h先静脉注射低分子肝素25mg,然后低分子肝素1mg/kg皮下注射,1次/d,共6d;对照组不用UK,其他治疗同治疗组。主要比较指标为30d内病死率和心肌梗塞发生率,并观察治疗组治疗前后凝血指数变化。结果:30d内心脏事件两组间差异显著(P<0.05),急性心肌梗塞发生率治疗组明显低于对照组(P<0.05),频发心绞痛发生率的减少亦优于对照组(第1周,P<0.01;第4周,P<0.05)。治疗组治疗前后凝血指数变化有显著性差异(P<0.05)。结论:小剂量尿激酶与低分子肝素联合治疗UAP可明显降低急性心肌梗塞和频发心绞痛的发生率。
Objective： To investigate the clinical effect of low- dose urokinase（UK）in combination with enoxaparin on unstable angina（UA）. Methods： The study was conducted in 158 patients with UA, They were randomly divided into low-dose UK group and placebo group, 79 patients each group. In low-dose UK group, low-dose UK 5000 IU/Kg was given per 30min for 3 d, in combination with enoxaparin 1 mg/Kg once daily for 6 d, Enoxaparin 25 mg Ⅳ bolus was given 1 h before low - dose UK thrombolytic therapy in the first day of admission. Enoxaparin was the same in low-dose UK group and placebo group. The main indexes for the comparison between the low-dose UK and placebo groups were fatality rate and incidence of AMI（cardiac event）within 30 d of enrollment. To observe change of coagulation indexes in low-does UK group befor and after the treatment. Results： There was statistically significant difference in cardiac event between two groups, （P 〈 0.05） the rate of AMI in low-dose UK group was much lower than that in placebo group, the differentce was significant（P〈 0. 05）. The incidence of frequent angina significantly decreased inpatients treated with low-dose UK as compared with patients in placebo（P〈 0. 05）. The difference of the change of coagulation indexes in low- dose UK group was significant before and after the trentment. Conclusion： Using low-dose UK in combination with enoxaparin might remarkably reduce the risk of AMI and the incidence of frequent angina.
出处
《中国药业》
CAS
2005年第12期80-81,共2页
China Pharmaceuticals
